We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Acadia Pharmaceuticals Inc | NASDAQ:ACAD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.34 | 2.03% | 17.05 | 16.40 | 17.63 | 17.57 | 16.84 | 16.84 | 1,627,841 | 01:00:00 |
By Mary de Wet
Acadia Pharmaceuticals Inc. said Monday the U.S. Food and Drug Administration accepted its new drug application of trofinetide for the treatment of Rett syndrome.
The FDA has granted a priority review and assigned a Prescription Drug User Fee Act action date of March 12, the biopharmaceutical company said. The FDA told Acadia that it isn't planning to hold an advisory committee meeting, the company said.
Trofinetide has already been granted fast track status and orphan drug designation for the treatment of Rett syndrome in the U.S. and the rare pediatric disease designation by the FDA.
Rett syndrome is a neurodevelopmental disorder that includes a period of normal development followed by regression with loss of language and hand function skills, impaired gait and development of hand stereotypes. It occurs worldwide in about one of every 10,000 to 15,000 female births, Acadia said.
The company has Nuplazid on the market to treat Parkinson's disease psychosis. Sales of the drug were $134.6 million in the three months ended June 30. Trofinetide is the next drug candidate in Acadia's pipeline.
Write to Mary de Wet at mary.dewet@dowjones.com
(END) Dow Jones Newswires
September 12, 2022 08:06 ET (12:06 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Acadia Pharmaceuticals Chart |
1 Month Acadia Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions